Background: To determine efficacy and safety of bevacizumab, a recombinant humanized antibody against vascular endothelial growth factor (VEGF), in the treatment of metastatic or locally advanced angiosarcoma and epithelioid hemangioendotheliomas.
introduction
Soft tissue sarcomas account for ∼1% of all adult malignancies. The subtype angiosarcoma comprises a small portion of this number [1] . Angiosarcomas occur in different clinical forms including primary angiosarcoma of the scalp or face which accounts for ∼15% of all head and neck sarcomas [2, 3] , postirradiation or in relation to chronic lymphedema [4, 5] , vinyl chloride-induced [6] or primary breast angiosarcomas [7, 8] . Treatment of localized angiosarcomas is surgical resection and often times pre-or post-operative radiation; however, with metastases or recurrence, systemic cytotoxic chemotherapy is warranted.
There are limited regimens available due to the rarity of disease and responses are usually minimal. Current regimens largely involve anthracyclines or taxanes. Responses to doxorubicin-based regimens are poor ranging between 17% and 34% [9] [10] [11] [12] [13] . At Memorial Sloan-Kettering in a small report of nine patients with angiosarcoma of the scalp and face treated with paclitaxel weekly or every 3 weeks, 8 patients had a response [14] . In a retrospective study of the European Organization for Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group, data were analyzed from patients with angiosarcoma who were treated with single-agent paclitaxel from 1996 to 2005. The response rate was 62% (21 of 32) in the whole series, 75% (6 of 8) in scalp angiosarcomas and 58% (14 of 24) in other primary sites. The median time to progression (TTP) was 7.6 months (range for the whole group [15] . Angiosarcoma is a rare malignancy and, as a result, there is a lack of robust data for efficacious therapies. With a larger number of patients receiving radiation for the treatment of breast cancer and other malignancies, the incidence of these tumors may rise. The current chemotherapy options have poor response rates; therefore, it is important to explore other therapeutic options.
Bevacizumab is a recombinant humanized antibody against vascular endothelial growth factor (VEGF), which has been shown to a primary regulator of angiogenesis and linked to tumor growth and metastases [16] . Up-regulation of this growth factor has been demonstrated in several tumors such as lung, breast, colorectal and angiosarcomas [17] . In a series of 34 angiosarcomas, over 90% immunohistochemical expression of certain VEGFs and their receptors were seen [18] . Preclinical trials with anti-angiogenic agents inhibiting VEGF in angiosarcoma tumor models have shown success, thus inferring these may be successful therapeutics options [19] . In two case studies of patients with angiosarcoma of the nose that were treated preoperatively with bevacizumab (5-10 mg/kg) and concurrent radiotherapy (50 Gy), followed by resection of the tumor bed both had a complete response with no residual disease [20] . This Simon 2-stage phase II study evaluated the efficacy, based on progression-free survival (PFS) as the primary end point, and tolerability of bevacizumab in angiosarcomas.
patients and methods
patient eligibility
Patients aged ≥18 years with histologically confirmed angiosarcoma ( patients with angiosarcoma of a vessel wall are not eligible for this study) or epithelioid hemangioendothelioma are eligible to include in the study. Patients must have measurable disease as defined by the Response Evaluation Criteria in Solid Tumors Committee (RECIST) criteria [21] . Any stage of disease is allowed, but the tumor must be deemed not surgically resectable or curable by any other therapeutic modality. Previous surgery, radiation or ≤3 chemotherapy regimens are allowed except no previous radiation in the 28 days preceding the study enrollment. The patients must be Eastern Cooperative Oncology Group (ECOG) performance status ≤1 with the following organ and marrow function within 21 days of the start of therapy: absolute neutrophil count ≥1500/μL, hemoglobin ≥9 g/dL, platelets ≥100 000/μL, creatinine ≤1.5 × upper limit of normal (ULN), total bilirubin ≤1.5 mg/dL, AST and ALT < 5 × ULN, PT/INR ≤ 1.5 × ULN, PTT ≤ 1.5 × ULN and an echocardiogram or multiple-gated acquisition scan showing a left ventricular ejection fraction of >49%. Patients were excluded if they had important cardiac or vascular disease defined by uncontrolled high blood pressure (>150/100), symptomatic heart failure, cardiac arrhythmia, unstable angina, myocardial infarction <6 months prior to treatment or clinically important peripheral vascular disease. Also patients with serious non-healing wounds, ulcers or bone fractures, evidence of a coagulopathy or on anticoagulants, evidence of central nervous system disease (brain metastases, primary brain tumor, prior cerebrovascular accident or seizures), history of abdominal fistula, GI perforation or intra-abdominal abscess <6 months prior to treatment were excluded. Participants provided written and witnessed informed consent before enrollment. Every local research ethics committees of the participating centers approved the study.
study therapy and dose modification
Study therapy consisted of bevacizumab 15 mg/kg IV infusion given on day 1 every 21 days, which was defined as the cycle length. Dosing and cycle length were chosen based on the published data supporting the safety of this treatment plan [22] . Treatment was continued until there was evidence of disease progression, intolerance, occurrence of an unacceptable adverse event, patient refusal or the decision by the physician to remove the patient from the study. Patients were evaluated for response every 6 weeks (2 cycles) for the first 12 weeks and then every 9 weeks (3 cycles) using RECIST criteria. The long-term follow-up period began after the last administration of bevacizumab for 2 years with evaluations every 3-4 months.
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There were no dose modifications for bevacizumab; therefore, if any adverse events occurred that required temporarily stopping therapy, bevacizumab was resumed at the previous dose. The longest duration that drug treatment was interrupted was 8 weeks. All adverse events were graded per the Common Terminology Criteria for Adverse Events, version 3.0, and the drug was withheld due to any grade 3 or 4 toxic effect related to hemorrhage, venous thrombosis, proteinuria, hepatic enzyme abnormalities or any other grade 3 or 4 non-hematologic adverse event. Also if any of the following occurred regardless of grade the drug was held: arterial thromboembolic event, GI perforation, platelet count <50 000/mm 3 for 3 weeks, allergic reactions and cytokine release syndrome/acute infusion reaction, wound dehiscence or reversible posterior leukoencephalopathy syndrome (RPLS).
statistical considerations
The primary objective of this study was to evaluate the median PFS of bevacizumab in treatment of angiosarcoma. Secondary objectives were to evaluate the duration of response, rate of stable disease, overall survival and the safety and tolerability of bevacizumab. An optimal two-stage Simon design was used. The Simon design allowed 12 patients to be entered in first stage of the study and if 3 or more patients have PFS >3 months the trial will be continued for a total of 31 patients.
Final data were transferred into IBM SPSS version 20. Transfer, descriptive and Kaplan-Meier survival analyses were provided.
results patients and treatment
Thirty-two patients with angiosarcoma or epithelioid hemangioendothelioma were enrolled in the study at four different cancer centers in the United States from August 2005 to April 2011. One patient never got treated per the principal investigator's decision and one patient withdrew consent before receiving treatment. Therefore, 30 patients were assessable for objective response and toxic effect. One of these patients, however, was lost to follow-up 3 months after starting treatment.
The median age was 62 with a range of 18-94 years old. Male patients represented 39% (12 of 31) and 61% were female (19 of 31). Most common sites of primary disease were cutaneous (including scalp, head and neck, face) at 32% (10 of 31) and visceral at 29% (9 of 31). Twelve patients, 39%, had metastatic disease upon presentation. All patients with epitheliod hemangioendothelioma had lymph node or metastatic disease. With respect to prior therapies, 11 patients had prior surgical resections, 11 patients had prior radiotherapy and 17 patients had at least one cycle of a prior chemotherapeutic agent. Nine of the 17 patients who had prior chemotherapy had one line, 4 patients had two lines and three lines of prior therapy. Detailed patient characteristics are listed in Table 1 .
response and survival
In keeping with the two-stage Simon design, analysis after the first 12 assessable patients, revealed 5 patients with a PFS >3 months. Given these results, the study was subsequently opened to the second stage and a total of 32 patients were accrued.
Four of the 30 patients (13%) had a partial response with two of the patients still receiving treatment after 34 (95 weeks) and 44 (133 weeks) cycles, respectively. One patient with a partial response experienced progressive disease at 7.1 weeks after achieving PR, while the other patient experienced progressive disease 14.6 weeks after achieving PR.
Of the 30 patients evaluated in the study, 10 of the patients had progressive disease after one or two cycles. Fifteen (50%) of the patients had stable disease after 2 cycles of treatment. Subsequently, four patients experienced progressive disease after 4 cycles, one after 6 cycles, four patients after 7 cycles, one after 13 cycles, one after 14 cycles and one after 26. The mean TTP for these patients was 8.6 cycles or 26 weeks. Two patients with stable disease experienced toxic effects (one not being study related) who required the removal from the study. One patient who had stable disease after seven cycles was removed from the study for insurance reasons.
The median follow-up for all patients was 43.9 weeks (10.9 months) with a range of 2.9-210 weeks. The median PFS was 12.4 weeks (Figure 1 ). Fourteen patients died while on the study with 12 as the result of progressive disease. One patient died of unknown causes, 51 weeks after discontinuation of bevacizumab. One patient was lost to follow-up 12 weeks after discontinuing bevacizumab and died 2 years following drug discontinuation. The median OS was 107 weeks (Figure 2 ).
Further breakdown, based on histology, is outlined in Table 2 . Of the 30 assessable patients, 23 were diagnosed with angiosarcoma. Of these patients, 2 (9%) of the 23 patients experienced a partial response, while 10 patients (43%) experience PD at first evaluation. The mean number of cycles received for this subgroup was 4.5 or 14 weeks. Median PFS and OS for these 23 patients are 12.0 and 52.7 weeks, respectively. Of the remaining assessable patients, seven were diagnosed with epithelioid hemangioendothelioma. Of these patients, two (29%) of the seven experienced a partial response, while only one patient (14%) experience PD at first evaluation. The mean number of cycles received for this subgroup was 17.3 or 52 weeks. Median PFS and OS for these seven patients are 39.1 and 142.6 weeks, respectively.
toxic effect
Bevacizumab was mostly well tolerated by patients. The most common toxic effects were grade 1 or 2 in intensity with fatigue being the most frequent. Hypertension was the second most common adverse event with only one out of seven reported being grade 3 in intensity. This is a common adverse event that has been seen in previous trials of bevacizumab [23] . The only grade 4 toxic effect that occurred was severe thrombocytopenia. Approximately 2 months after starting bevacizumab, one patient had a hepatic resection and splenectomy that was complicated by pleural effusion and colitis. After surgery, the patient continued therapy and tolerated a total of 13 cycles. Overall, the adverse events seen (Table 3) were similar to those observed in previous trials of bevacizumab for treatment of other tumor types such as colorectal and breast carcinoma [23, 24] .
discussion
We report the first prospective, multicenter, phase II clinical trial for metastatic or locally advanced angiosarcoma and epithelioid hemangioendothelioma, using targeted therapy. Current therapy for localized angiosarcoma is primarily surgical resection with wide margins combined with adjuvant radiation [25] . No formal phase III trials assessing the efficacy of adjuvant radiation have been conducted, but case series show improved overall survival [26] . Nonetheless, these tumors have a propensity for metastases and recurrence and the current chemotherapy regimens produce minimal response. Overall 5-year survival for angiosarcoma is typically between 30% and 50% [27, 28] . The benefits from standard chemotherapies, in the metastatic disease setting, are somewhat difficult to discern. Most studies have been severely hampered by the admixture of a variety of histologic subtypes in the analysis of outcome, making it difficult to assess the clinical activity of any given treatment. The interpretation of clinical trial results will be heavily weighted by the distribution of original articles Annals of Oncology histologic subtypes. This, in turn, complicates the assessment of chemotherapy efficacy, making it impossible to determine whether high or low response rates are due to the specific treatment or to the specific population under study. In contrast to virtually every other histology, angiosarcomas, particularly those arising on the scalp, are sensitive to taxanes. A prospective phase II study of paclitaxel by the French Sarcoma group demonstrated PFS rates of 74% and 45% after 2 and 4 months, respectively [29] . With a median follow-up of 8 months, the median TTP was 4 months and the median overall survival was 8 months. Based on a complete response observed in a patient with angiosarcoma of the scalp treated with paclitaxel in a phase II trial, Memorial Sloan-Kettering Cancer Center treated a cohort of patients with angiosarcoma of the scalp or face with paclitaxel as single agent. Of the nine patients, eight had major responses (four partial responses and four clinical complete responses) and one had a minor response, for a major response rate of 89%. The median duration of response was 5 months (range 2-13 months) [14] .
In this study, single-agent bevacizumab, an effective antiangiogenic agent, was used for treatment of angiosarcoma by exploiting the pathologic pathways underlying the disease. The results of this phase II trial with 30 patients are promising with four patients showing a partial response and half the patients showing stable disease with mean TTP of 26 weeks. The addition of patients with epitheliod hemangioendotheliomas was an important aspect of the trial, to gain information on this rare variant of sarcoma. Given the small number of patients, further conclusions cannot be made; however, it is important to note that all patients with hemangioendotheliomas had advanced disease. In addition, bevacizumab was found to well tolerated with only one grade 4 adverse event. The toxic effect was manageable and expected.
Other targeted agents that also inhibit VEGF have shown mixed results in phase II trials. A phase II trial with sunitinib, a broad-spectrum tyrosine kinase inhibitor, in 48 metastatic soft tissue sarcomas, with two patients with angiosarcomas, demonstrated no responses were seen with the angiosarcoma patients [30] . A study of sorafenib, a tyrosine kinase inhibitor that has action against VEGF, included a cohort of patients with angiosarcoma. This large trial involved 122 advanced soft tissue sarcomas with 37 angiosarcomas. The overall response rate within the angiosarcomas was 14% with four patients showing a partial response and one with a complete response. Median PFS was 3.8 months [31] . These results are comparable to our findings in terms of response rate and PFS. One difference in our study was the inclusion of epithelioid hemangioendotheliomas, which are considered in the same pathologic spectrum as angiosarcomas, albeit lower grade with a more indolent course.
The results seen in this trial and above are encouraging and argue for a randomized study of anthracycline or taxane-based chemotherapy with or without bevacizumab. The mainstay of treatment for metastatic STS is the anthracycline doxorubicin. The addition of other agents such as ifosfamide, dacarbazine or cyclophosphamide, vincristine, and dactinomycin has shown an increase in the response rate, without an advantage in overall survival [32] . The rationale for the addition of bevacizumab to chemotherapy stems from randomized phase 3 studies comparing chemotherapy with or without bevacizumab 
Annals of Oncology original articles
as first-line treatment for advanced epithelial cancers. In reviewing data from breast [33] [34] [35] , prostate [36] , ovarian [37] , lung [38] [39] [40] , pancreas [41, 42] and colorectal [43, 44] cancers, statistically significant advances in PFS and in some cases overall survival have been reported. Given these data, further evaluation of bevacizumab in combination with chemotherapy is warranted in angiosarcomas and epithelioid hemangioendotheliomas. While a phase II study of doxorubicin and bevacizumab for patients with metastatic soft tissue sarcomas revealed a response rate that is not higher than that expected for single-agent doxorubicin, TTP and overall survival data are encouraging and suggest further investigation [45] . The 12% response rate for these patients was no greater than that observed for single-agent doxorubicin. However, 65% of patients with stable disease lasting four cycles or longer suggests further study is warranted. The observed cardiac toxic effect, despite close monitoring and standard use of dexrazoxane, suggests that other drug combinations are warranted, such as bevacizumab with either paclitaxel or docetaxel. This phase II study illustrates further that clinical trials in rare sarcoma subtypes can accrue successfully based on collaborative efforts and further evaluation of bevacizumab in combination with a chemotherapeutic agent is feasible and definitely warranted, for patients with angiosarcomas and epitheliod hemangioendotheliomas. 
